BioSpace News Archive

Ocugen, Inc. announced the Compensation Committee of the Board of Directors of Ocugen approved the grant of stock options to purchase an aggregate of 137,250 shares of its common stock and restricted stock units covering an aggregate of 23,000 shares of common stock to seven hired employees.

Pfizer Inc. and BioNTech SE announced that the U.S. Food and Drug Administration’s Vaccines and Related Biological Products Advisory Committee voted unanimously to recommend the FDA grant Emergency Use Authorization for a booster dose of COMIRNATY® in individuals 65 years of age and older and individuals at high risk of severe COVID-19.

Sutro Biopharma, Inc. announced that on September 15, 2021, the Compensation Committee of Sutro’s Board of Directors granted restricted stock unit awards representing an aggregate of 150,000 shares of Sutro common stock and stock options to purchase an aggregate of 145,000 shares of Sutro common stock to 3 new employees.

Tyra Biosciences, Inc. announced the closing of its initial public offering of 12,420,000 shares of common stock, which includes the exercise in full by the underwriters of their option to purchase 1,620,000 additional shares, at an initial public offering price of $16.00 per share.

Arena Pharmaceuticals, Inc. announced that the Compensation Committee of its Board of Directors granted to 20 new employees inducement stock options to purchase an aggregate of 33,340 shares of its common stock and 15,655 inducement restricted stock units.

Medifocus, Inc. announced it has commenced restructuring proceedings by filing for creditor protection to allow the Company to address the debt on its balance sheet.

Vertex Pharmaceuticals Incorporated (Canada) (Nasdaq: VRTX) today announced that it has signed a Letter of Intent (LOI) with the pan-Canadian Pharmaceutical Alliance (pCPA), which represents an agreement in principle regarding the public reimbursement of PrTRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) for eligible patients with cystic fibrosis (CF).

PerkinElmer, Inc. (NYSE: PKI) a global leader committed to innovating for a healthier world, today announced it has completed its acquisition of BioLegend, a leading, worldwide provider of life science antibodies and reagents for a total consideration of approximately $5.25 billion.

Exelixis, Inc. (Nasdaq: EXEL) today announced that the U.S. Food and Drug Administration (FDA) approved CABOMETYX® (cabozantinib) for the treatment of adult and pediatric patients 12 years of age and older with locally advanced or metastatic differentiated thyroid cancer (DTC) that has progressed following prior vascular endothelial growth factor receptor (VEGFR)-targeted therapy and who are radioactive iodine-refractory or ineligible.

Astellas Pharma Inc. and Pfizer Inc. announced ahead of the European Society for Medical Oncology Congress 2021 that XTANDI® improved overall survival in the ARCHES study in men with metastatic hormone-sensitive prostate cancer.